Wker Bioscience

Shanghai Weike Biotechnology Co., Ltd. was established on March 8, 2021. The company is an innovative enterprise that conducts integrated viral insertion site analysis (ISA) in line with domestic regulatory requirements and holds a leading position in the field of gene therapy safety evaluation. Wker Bioscience primarily focuses on technical development and services in areas such as risk assessment of insertional mutations in gene therapy, high-precision CRISPR/Cas9 quantitative off-target analysis, vector copy number (VCN), vector quality control, immune repertoire analysis, and efficient sgRNA screening. Its main businesses include risk assessment of insertional mutations in gene therapy, high-precision CRISPR/Cas9 quantitative off-target analysis, and sgRNA screening. The LTA-PCR and TES systems it relies on are the world’s first validated ISA detection methods, which have completed the risk assessment of insertional mutations for multiple gene therapy drugs approved by the FDA and EMA.